Black Diamond Therapeutics, Inc. (BDTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David M. Epstein
Employees:
139 MAIN STREET, CAMBRIDGE, MA 02142
617-417-5868

Black Diamond Therapeutics, Inc. is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond Therapeutics goal is to bring precision oncology medicine to a greater number of patients. Black Diamond Therapeutics targets undrugged mutations in patients with genetically-defined cancers. The foundation of Black Diamond Therapeutics is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Black Diamond Therapeutics principal executive office is located at 139 Main Street, Cambridge, MA 02142

Data derived from most recent annual or quarterly report
Market Cap 291.158 Million Shares Outstanding36.214 Million Avg 30-day Volume 233.272 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 37.76 / 7.55 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from BDTX instead.

View recent insider trading info

Funds Holding BDTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BDTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

INGRAM ROBERT ALEXANDER

9,306 2021-09-17 4

BEHBAHANI ALI

  • Director
3,451,644 2021-09-17 3

BUCK ELIZABETH CHIEF SCIENTIFIC OFFICER

95,192 2021-09-15 1

VELLECA MARK A.

0 2021-08-09 2

BOLZON BRADLEY J PHD

  • Director
  • 10% Owner
15,000 2021-06-18 11

DHINGRA KAPIL

  • Director
15,000 2021-06-18 3

MENZEL GARRY E

  • Director
15,000 2021-06-18 2

SHAH RAJEEV M.

  • Director
15,000 2021-06-18 4

KULKARNI SAMARTH

  • Director
15,000 2021-06-18 2

MAYWEG ALEXANDER

  • Director
15,000 2021-06-18 1

HATZIS-SCHOCH BRENT SEE REMARKS

  • Officer
168,874 2021-05-12 9

ROBERTS CHRISTOPHER D. CHIEF SCIENTIFIC OFFICER

  • Officer
166,809 2021-05-03 10

EPSTEIN DAVID M. SEE REMARKS

  • Officer
  • Director
0 2021-02-17 5

HUMPHREY RACHEL CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-17 1

LEGGETT THOMAS CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-17 4

VERSANT VENTURE CAPITAL VI, L.P.

VERSANT VOYAGEURS I PARALLEL, L.P.

VERSANT VOYAGEURS I, L.P.

VERSANT VANTAGE I, L.P.

  • 10% Owner
6,428,564 2020-12-14 5

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2020-02-03 0

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
No longer subject to file 2020-02-03 0

MOTT DAVID M

  • 10% Owner
0 2020-01-29 0

MAKOWER JOSHUA

  • 10% Owner
0 2020-01-29 0

SANDELL SCOTT D

  • 10% Owner
0 2020-01-29 0

BASKETT FOREST

  • 10% Owner
0 2020-01-29 0

WALKER PAUL EDWARD

  • 10% Owner
0 2020-01-29 0

SONSINI PETER W.

  • 10% Owner
0 2020-01-29 0

FLORENCE ANTHONY A. JR.

  • 10% Owner
0 2020-01-29 0

MAKHZOUMI MOHAMAD

  • 10% Owner
0 2020-01-29 0

NEW ENTERPRISE ASSOCIATES 16, L.P.

NEA PARTNERS 16, L.P.

NEA 16 GP, LLC

  • 10% Owner
0 2020-01-29 0

CHANG CARMEN

  • 10% Owner
0 2020-01-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

INGRAM ROBERT ALEXANDER

2021-09-23 17:33:31 -0400 2021-09-17 A 1,869 $9.90 a 9,306 direct 5.0592 -8.7191 5.0592 2 -8.9343 5

BEHBAHANI ALI - Director

2021-09-23 17:43:57 -0400 2021-09-17 A 1,326 $9.90 a 2,887 direct 5.0592 -8.7191 5.0592 2 -8.9343 5

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 22:15:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 21:45:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 21:15:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 20:45:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 20:15:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 19:45:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 19:15:03 UTC -0.682 0.752 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 18:45:03 UTC -0.6826 0.7526 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 18:15:03 UTC -0.6826 0.7526 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 17:45:03 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 17:15:03 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 16:45:04 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 16:15:03 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 15:45:03 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 15:15:03 UTC -0.4893 0.5593 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 14:45:03 UTC -0.438 0.508 300000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 14:15:05 UTC -0.438 0.508 250000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 13:45:03 UTC -0.438 0.508 250000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 13:15:03 UTC -0.438 0.508 250000
BLACK DIAMOND THERAPEUTICS I BDTX 2021-10-26 12:45:03 UTC -0.438 0.508 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
INVESTMENT MANAGERS SERIES TRUST- 361 Global Long/Short Equity Fund BDTX -62997.0 shares, $-602251.32 2021-07-31 N-PORT

Elevate your investments